Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI.

J Clin Oncol. 2009 Jan 1;27(1):114-9. doi: 10.1200/JCO.2008.16.8021. Epub 2008 Dec 1.

2.

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP.

N Engl J Med. 1993 Apr 8;328(14):1002-6.

3.
4.

Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.

Gordon LI, Andersen J, Colgan J, Glick J, Resnick GD, O'Connell M, Cassileth PA.

Cancer. 1995 Feb 1;75(3):865-73.

5.

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2007 Jan;18(1):149-57. Epub 2006 Oct 3.

6.

[Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].

Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.

Srp Arh Celok Lek. 1998 Sep-Oct;126(9-10):345-8. Serbian.

PMID:
9863405
7.

Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.

Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA Jr.

Semin Hematol. 1987 Apr;24(2 Suppl 1):21-5.

PMID:
2438778
8.

Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.

Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI.

J Clin Oncol. 1990 Dec;8(12):1951-8.

PMID:
1700079
9.

Advances in chemotherapy for large cell lymphoma.

Coleman M, Gerstein G, Topilow A, Lebowicz J, Berhardt B, Chiarieri D, Silver RT, Pasmantier MW.

Semin Hematol. 1987 Apr;24(2 Suppl 1):8-20.

PMID:
2438781
10.

Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.

Fisher RI, Longo DL, DeVita VT Jr, Hubbard SM, Miller TP, Young RC.

Ann Oncol. 1991 Jan;2 Suppl 1:33-5. Review.

PMID:
1710487
11.

MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M, et al.

J Clin Oncol. 1994 Jul;12(7):1366-74.

PMID:
7517442
12.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
13.

Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.

Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, Fisher RI.

Semin Hematol. 1988 Apr;25(2 Suppl 2):17-22.

PMID:
2456619
14.
15.

A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).

Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.

Haematologica. 2000 Mar;85(3):263-8.

16.
17.

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.

Longo DL, DeVita VT Jr, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI, et al.

J Clin Oncol. 1991 Jan;9(1):25-38. Erratum in: J Clin Oncol 1991 Apr;9(4):710.

PMID:
1702144
18.

Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.

Linassier C, Desablens B, Lefrancq T, Le Prise PY, Harousseau JL, Jacob C, Gandhour C, Haillot O, Lucas V, Leloup R, Escoffre M, Colombat P, Tabuteau S; GOELAMS Study Group.

Clin Lymphoma. 2002 Dec;3(3):167-72.

PMID:
12521394
19.

Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.

Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.

Haematologica. 1998 Sep;83(9):800-11.

20.

Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.

Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, DeVita VT Jr, Young RC.

J Clin Oncol. 1994 Oct;12(10):2153-9. Erratum in: J Clin Oncol 1996 Jun;14(6):1969.

PMID:
7523607
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk